What it's for (Indications)
- Mesalazine, a 5-aminosalicylic acid (5-ASA) derivative, is primarily indicated for the treatment of mild to moderate ulcerative colitis (UC) in adults and pediatric patients.
- It is extensively used for both the induction of remission and the maintenance of remission in patients with UC.
- Its therapeutic efficacy stems from its direct anti-inflammatory action on the inflamed colonic mucosa.
- While its role in Crohn's disease (CD) is less prominent and generally considered for mild to moderate disease, particularly involving the colon or ileocolonic region, its primary established indication remains ulcerative colitis.
- The specific formulation, such as oral delayed-release tablets, extended-release capsules, or rectal preparations (suppositories, enemas), is chosen to ensure targeted drug delivery to the affected segments of the gastrointestinal tract, optimizing local anti-inflammatory effects.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of mesalazine is highly variable and contingent upon the specific formulation (e.g., oral tablets, granules, suppositories, enemas), the patient's age, weight, and the clinical indication (i.e., induction versus maintenance of remission in ulcerative colitis). For oral formulations in adults, typical dosages for the induction of remission in mild to moderate UC can range from 2.4 grams to 4.8 grams per day, often administered in divided doses. Maintenance dosages are generally lower, commonly ranging from 1.2 grams to 2.4 grams per day. Rectal formulations are specifically utilized for proctitis or distal colitis; for instance, suppositories might be dosed at 1 gram once or twice daily, while enemas are often prescribed as 4 grams daily. Pediatric dosages are typically calculated based on body weight. It is imperative that dosage regimens strictly adhere to the prescribing information for the specific mesalazine product and are determined by a qualified healthcare professional. |
Safety & Warnings
Common Side Effects
- Mesalazine is generally well-tolerated, but patients may experience a spectrum of adverse effects.
- Common side effects often include gastrointestinal disturbances such as headache, nausea, abdominal pain, diarrhea, flatulence, and dyspepsia.
- Less common but potentially more serious adverse reactions involve hypersensitivity phenomena, which can manifest as skin rashes, fever, or more severe systemic reactions like myocarditis, pericarditis, nephritis, and pneumonitis.
- Renal impairment, including acute interstitial nephritis, has been reported and necessitates diligent monitoring of kidney function during treatment.
- Pancreatitis is a rare but critical adverse event requiring immediate medical attention.
- Other reported side effects include alopecia, dizziness, and paradoxical worsening or exacerbation of colitis symptoms.
- Rare but severe hematologic abnormalities, such as agranulocytosis, aplastic anemia, and thrombocytopenia, mandate prompt discontinuation and comprehensive hematological evaluation.
Serious Warnings
- Black Box Warning: **Serious Warnings** Mesalazine (5-aminosalicylic acid) does not currently carry an FDA-mandated Black Box Warning. However, healthcare professionals and patients should be acutely aware of several serious warnings and precautions. These include the potential for significant renal impairment, such as acute and chronic interstitial nephritis, which necessitates regular monitoring of renal function, especially in individuals with pre-existing renal disease or those concomitantly receiving nephrotoxic medications. Hypersensitivity reactions, which can manifest as myocarditis, pericarditis, pneumonitis, or severe cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), demand immediate discontinuation of the drug. Exacerbation of colitis symptoms has been reported, requiring careful differentiation from disease worsening, as it may indicate a hypersensitivity reaction. Pancreatitis is a rare but critical adverse event requiring prompt cessation of therapy. Furthermore, rare but serious blood dyscrasias (e.g., agranulocytosis, aplastic anemia) have been reported, mandating immediate medical evaluation if suspected. Patients must be educated to report any new or worsening symptoms to their healthcare provider without delay.
- Several significant warnings are associated with mesalazine therapy.
- Renal impairment, encompassing both acute and chronic interstitial nephritis, has been documented, thereby mandating routine monitoring of renal function, particularly in patients with pre-existing kidney disease or those concurrently receiving nephrotoxic agents.
- Hypersensitivity reactions, including but not limited to myocarditis, pericarditis, pleurisy, and severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have occurred; mesalazine must be immediately discontinued if such reactions are suspected.
- Exacerbation of colitis symptoms, which can sometimes mimic an acute worsening of ulcerative colitis or represent a hypersensitivity reaction (e.
- g.
- , fever, rash, abdominal pain, increased disease activity), has been reported.
- Pancreatitis is a rare but serious complication.
- Caution is also advised in patients with known or suspected hepatic impairment.
- Furthermore, rare cases of blood dyscrasias have been reported; patients presenting with unexplained bleeding, bruising, purpura, sore throat, fever, or malaise should undergo urgent hematologic assessment.
How it Works (Mechanism of Action)
Mesalazine (5-aminosalicylic acid, 5-ASA) is believed to exert its primary therapeutic effects through a local, topical action on the inflamed intestinal mucosa rather than via systemic absorption. While its precise mechanism remains under active investigation, it is thought to involve multiple anti-inflammatory pathways. Mesalazine is known to inhibit cyclooxygenase (COX) and lipoxygenase pathways, thereby reducing the synthesis of inflammatory mediators such as prostaglandins and leukotrienes. It also functions as an antioxidant, scavenging reactive oxygen species and inhibiting the oxidative damage and inflammatory cascades associated with inflammatory bowel disease. Additionally, mesalazine may modulate immune cell function, including inhibiting the migration and activity of neutrophils, and may suppress the production of pro-inflammatory cytokines like TNF-alpha and interleukin-1. The various formulations are specifically designed to deliver mesalazine directly to the affected segments of the colon, maximizing its local anti-inflammatory benefits.